96 related articles for article (PubMed ID: 17983195)
1. In vitro study of staphylococci susceptibility to gatifloxacin.
Tuchiluş C; Poiată A; Buiuc D
Rev Med Chir Soc Med Nat Iasi; 2007; 111(2):516-9. PubMed ID: 17983195
[TBL] [Abstract][Full Text] [Related]
2. In vitro efficacy and pharmacodynamic indices for antibiotics against coagulase-negative staphylococcus endophthalmitis isolates.
Harper T; Miller D; Flynn HW
Ophthalmology; 2007 May; 114(5):871-5. PubMed ID: 17383732
[TBL] [Abstract][Full Text] [Related]
3. In vitro fluoroquinolone resistance in staphylococcal endophthalmitis isolates.
Miller D; Flynn PM; Scott IU; Alfonso EC; Flynn HW
Arch Ophthalmol; 2006 Apr; 124(4):479-83. PubMed ID: 16606872
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of fluoroquinolones against ocular bacterial isolates in São Paulo, Brazil.
Oliveira AD; D'Azevedo PA; Francisco W
Cornea; 2007 Feb; 26(2):194-8. PubMed ID: 17251812
[TBL] [Abstract][Full Text] [Related]
5. Fluoroquinolone susceptibilities to methicillin-resistant and susceptible coagulase-negative Staphylococcus isolated from eye infection.
Oliveira AD; Höfling-Lima AL; Belfort R; Gayoso Mde F; Francisco W
Arq Bras Oftalmol; 2007; 70(2):286-9. PubMed ID: 17589701
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of levofloxacin against coagulase-positive and -negative staphylococci.
Cafiso V; Messina C; Santagati M; Campanile F; Bonfiglio G; Stefani S
Drugs Exp Clin Res; 2001; 27(3):107-11. PubMed ID: 11447768
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of the new quinolone WCK 771 against staphylococci.
Jacobs MR; Bajaksouzian S; Windau A; Appelbaum PC; Patel MV; Gupte SV; Bhagwat SS; De Souza NJ; Khorakiwala HF
Antimicrob Agents Chemother; 2004 Sep; 48(9):3338-42. PubMed ID: 15328094
[TBL] [Abstract][Full Text] [Related]
8. [In vitro activity of sparfloxacin against methicillin-resistant staphylococci].
Wallrauch C; Voss A; Milatovic D; Braveny I
Arzneimittelforschung; 1995 Jun; 45(6):723-5. PubMed ID: 7646580
[TBL] [Abstract][Full Text] [Related]
9. An ophthalmologist's guide to understanding antibiotic susceptibility and minimum inhibitory concentration data.
Kowalski RP; Yates KA; Romanowski EG; Karenchak LM; Mah FS; Gordon YJ
Ophthalmology; 2005 Nov; 112(11):1987. PubMed ID: 16183128
[TBL] [Abstract][Full Text] [Related]
10. Comparison of in vitro susceptibilities of Gram-positive cocci isolated from ocular infections against the second and fourth generation quinolones at a tertiary eye care centre in South India.
Reddy AK; Garg P; Alam MR; Gopinathan U; Sharma S; Krishnaiah S
Eye (Lond); 2010 Jan; 24(1):170-4. PubMed ID: 19229279
[TBL] [Abstract][Full Text] [Related]
11. Fluoroquinolone resistance in staphylococci: new challenges.
Sanders CC; Sanders WE; Thomson KS
Eur J Clin Microbiol Infect Dis; 1995; 14 Suppl 1():S6-11. PubMed ID: 7729471
[TBL] [Abstract][Full Text] [Related]
12. Surveillance of the susceptibility of ocular bacterial pathogens to the fluoroquinolone gatifloxacin and other antimicrobials in Europe during 2001/2002.
Morrissey I; Burnett R; Viljoen L; Robbins M
J Infect; 2004 Aug; 49(2):109-14. PubMed ID: 15236917
[TBL] [Abstract][Full Text] [Related]
13. Activity of telavancin and comparator antimicrobial agents tested against Staphylococcus spp. isolated from hospitalised patients in Europe (2007-2008).
Mendes RE; Sader HS; Jones RN
Int J Antimicrob Agents; 2010 Oct; 36(4):374-9. PubMed ID: 20598860
[TBL] [Abstract][Full Text] [Related]
14. Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus.
Metzler K; Hansen GM; Hedlin P; Harding E; Drlica K; Blondeau JM
Int J Antimicrob Agents; 2004 Aug; 24(2):161-7. PubMed ID: 15288315
[TBL] [Abstract][Full Text] [Related]
15. Susceptibilities of healthcare- and community-associated methicillin-resistant staphylococci to the novel des-F(6)-quinolone DX-619.
Watanabe S; Ito T; Hiramatsu K
J Antimicrob Chemother; 2007 Dec; 60(6):1384-7. PubMed ID: 17890283
[TBL] [Abstract][Full Text] [Related]
16. Quinolone resistance in Staphylococci: activities of new nonfluorinated quinolones against molecular targets in whole cells and clinical isolates.
Roychoudhury S; Catrenich CE; McIntosh EJ; McKeever HD; Makin KM; Koenigs PM; Ledoussal B
Antimicrob Agents Chemother; 2001 Apr; 45(4):1115-20. PubMed ID: 11257024
[TBL] [Abstract][Full Text] [Related]
17. Serum bactericidal activity of the methoxyfluoroquinolones gatifloxacin and moxifloxacin against clinical isolates of Staphylococcus species: are the susceptibility breakpoints too high?
Stein GE; Schooley S; Kaatz GW
Clin Infect Dis; 2003 Nov; 37(10):1392-5. PubMed ID: 14583876
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility of recent clinical isolates to temafloxacin (A-63004) and other antimicrobial agents.
Qadri SM; Ueno Y; Burns JJ; Almodovar E; Rabea N
Drugs Exp Clin Res; 1992; 18(8):311-7. PubMed ID: 1338041
[TBL] [Abstract][Full Text] [Related]
19. In vitro susceptibilities of bacterial isolates from conjunctival flora to gatifloxacin, levofloxacin, tosufloxacin, and moxifloxacin.
Yamada M; Hatou S; Yoshida J
Eye Contact Lens; 2008 Mar; 34(2):109-12. PubMed ID: 18327047
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial susceptibility testing of newer quinolones against gram positive and gram negative clinical isolates.
Iffat W; Shoaib MH; Muhammad IN; Rehana ; Tasleem S; Gauhar S
Pak J Pharm Sci; 2010 Jul; 23(3):245-9. PubMed ID: 20566434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
